Industry News
Pharmaceutical Industry News
F.D.A. Refuses to Review Moderna Flu Vaccine
The vaccine maker’s shots involve the successful Covid vaccines’ RNA technology. Health Secretary Robert F. Kennedy Jr. has broadly rejected it, canceling millions of dollars in research projects.
I Just Returned From China. We Are Not Winning.
If we are going to be competitive with China, we have to get our economic house in order.
Late Tuesday, Fujifilm…
Late Tuesday, Fujifilm Biotechnologies opened the doors to its expanded United Kingdom site in Teesside, capping off a 400 million pound (around $546 million) project that’s been in the works since late 2021. With the
PharmaEssentia will spend $46…
PharmaEssentia will spend $46 million to build a manufacturing facility in Puerto Rico. The move forms part of the Taiwanese biotech’s global expansion strategy to support demand for its rare blood disease treatment Besremi.
With Incyte set to lose patent…
With Incyte set to lose patent protection for its blood cancer standout, Jakafi, in late 2028, the company will have to rely more on its topical cream, Opzelura. In its fourth full year on the
A batch of untitled letters posted…
A batch of untitled letters posted on the FDA’s database in recent days takes aim at what the agency has termed “false or misleading” drug ads from the likes of Novo Nordisk, argenx and Sobi.
The agreement includes mRNA…
The agreement includes mRNA vaccine supply and a technology transfer that allows Mexico's Laboratorios Liomont to produce Moderna's 2025-2026 COVID vaccine.
After ending 2025 with a strong…
After ending 2025 with a strong fourth quarter, AstraZeneca management has doubled down on its ambitious “$80 billion by 2030” revenue target, outlining a roadmap to have more than 25 blockbuster medicines by the end
Paul McKenzie, Ph.D., who’s…
Paul McKenzie, Ph.D., who’s served as CSL’s chief executive and managing director for the past three years, is retiring Tuesday, with company insider Gordon Naylor set to take up the CEO post on an interim
Novo’s star-studded Wegovy pill…
Novo's star-studded Wegovy pill promotion earned the top spot among the pharma ads that played during the Super Bowl, according to TV outcomes company EDO's ranking of the ads that earned the most engagement.
Novartis CEO Vas Narasimhan saw…
Novartis CEO Vas Narasimhan saw his realized compensation swell by 30% in 2025, reaching 24.9 million Swiss francs ($32.4M) as the Swiss pharma giant exceeded its long-term financial and innovation targets.
A new campaign from Otsuka aims to…
A new campaign from Otsuka aims to educate healthcare professionals about the far-reaching impacts of attention-deficit/hyperactivity disorder on patients’ lives, beyond just the diagnostic symptoms of the condition.
Bristol Myers Squibb has signed an…
Bristol Myers Squibb has signed an agreement to partner with Evinova’s AI-native clinical development platform across the company’s global portfolio in an effort to improve efficiency and cut costs.
The agreement will see Phlow as…
The agreement will see Phlow as the first drugmaker to produce epinephrine injection API in the U.S., while Fresenius will work on formulation and finished doses to ship to U.S. hospitals and clinics, the companies
Hims & Hers caused a firestorm…
Hims & Hers caused a firestorm last week when it revealed that it planned to launch a knockoff version of Novo Nordisk's new oral weight loss medicine. But the reaction to the move has caused
TrumpRx: What to Know About Insurance Benefits, Pricing and Savings
People may be able to pay less for prescriptions with their insurance rather than via the new government website. The Trump drugstore is meant to help people buy medications using their own money.
As the 2026 Winter Olympics get…
As the 2026 Winter Olympics get underway in Italy this week, Eli Lilly—a partner of both Team USA and the Milan Cortina Games as a whole—is rolling out a new corporate campaign inspired by the
Biogen recorded declining sales…
Biogen recorded declining sales for Spinraza in each of the four quarters of 2025, but the Massachusetts drugmaker sees positive signs with the recent launch of its high-dose version of the spinal muscular atrophy treatment
NPC President and CEO John…
NPC President and CEO John O’Brien discusses the impact of policy on patient access and innovation.
The stock price of BridgeBio…
The stock price of BridgeBio plunged 15% Thursday on Pfizer's reported decision to withdraw a tafamidis patent in the EU, triggering fears of earlier generic entry in the blockbuster ATTR-CM market.